AARD
Aardvark Therapeutics, Inc. Common StockNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage ready
Factor tilt: Anti-Quality Micro Cap
$4.04-9.21%
Close Oct 13, 2026
- Market cap
- $88.26M
- 1 month
- -27.2%
- 3 months
- -39.4%
- 1 year
- -75.2%
- 52-week range
- $3.48$15.82
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.75Quarter to Sep 30, 2026 · 8 analysts · revenue $0
- Short interest
- 4.3% of float474.1K shares · settled Sep 30, 2026 · +11.6% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$69.89M
- Free cash flow
- -$69.41M
- Book value
- $74.8M
- Total debt
- $677K
- P/E
- —
- Price / sales
- —
- Price / book
- 1.2×
- FCF yield
- -78.6%
- Net margin
- —
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if AARD is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
11 top institutions tracked
as of 2026-Q2 (filed 2026-09-22)
Insider context
Sentiment: neutral
Last trade: sell 34 days ago
Red flags: 4
Largest 13-F holders · Q2 2026
72 filers reported a long position in AARD for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Decheng Capital LLC | $22.6M | 3.9M | Unchanged |
| CITADEL ADVISORS LLC | $7.4M | 1.3M | +3.2% |
| Laurion Capital Management LP | $6M | 1M | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.2M | 562.9K | +1.6% |
| AQR CAPITAL MANAGEMENT LLC | $2.8M | 480.2K | +257.1% |
| EcoR1 Capital, LLC | $2.3M | 396.2K | New |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1.7M | 300K | Unchanged |
| BlackRock, Inc. | $1.1M | 187K | -76.4% |
| GEODE CAPITAL MANAGEMENT, LLC | $863.5K | 149.8K | -51.6% |
| CANTOR FITZGERALD, L. P. | $671.5K | 116.6K | +74.8% |
Get the Full Analysis for AARD
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.